| Noncolorectal Gastrointestinal Cancer |
0 |
0.98 |
| Cancer |
0 |
0.95 |
| Otolaryngology |
0 |
0.8 |
| Esophageal Cancer |
0 |
0.79 |
| Breast Cancer |
0 |
0.77 |
| Gastric Cancer |
0 |
0.77 |
| Ovarian Cancer |
0 |
0.77 |
| Genomic Medicine |
0 |
0.72 |
| Pancreatic Cancer |
0 |
0.71 |
| Cervical Cancer |
0 |
0.7 |
| Colorectal Cancer |
0 |
0.7 |
| Endometrial Cancer |
0 |
0.7 |
| Prostate Cancer |
0 |
0.62 |
| Biliary Tract |
0 |
0.14 |
| Genetic Testing |
0 |
0.14 |
| Esophagus |
0 |
0.12 |
| Genetics |
0 |
0.1 |
| Breast |
0 |
0.07 |
| Poly ADP-Ribose Polymerase (PARP) Inhibitor |
0 |
0.07 |
| Prostate |
0 |
0.07 |
| Clinical Guidelines |
0 |
0.05 |
| Clinical Management |
0 |
0.02 |
| Clinical Research |
0 |
0.02 |
| Europe |
0 |
0.02 |
| Healthcare and Medical Technology |
0 |
0.02 |
| Stomach |
0 |
0.02 |